University of Illinois at Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Illinois at Chicago sits in the top decile of US sponsors by registered trial count (#83 of 15,742 sponsors by registered trial count).
University of Illinois at Chicago: 430 sponsored US clinical trials, 115 recruiting.
University of Illinois at Chicago sponsors 430 registered US clinical trials on ClinicalTrials.gov, 115 of them currently recruiting, and 236 completed. 30 of these trials are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 10 trials.
Top-decile sponsor footprint
University of Illinois at Chicago ranks in the top decile of sponsors by registered trial count (#83 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
236 of 271 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
430 total, page 7 of 9
Resistance Exercise Training in Chronic Kidney Disease
NCT03120416
Arabin Pessary Combine With Vaginal Progesterone Compare With Vaginal Progesterone Alone to Prevent Preterm Delivery in Singleton Pregnancies
NCT03052270
A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
NCT03165786
Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults
NCT03129048
Time Restricted Feeding for Weight Loss and Cardio-protection
NCT02948517
Evaluating the Use of an Informational Head and Neck Cancer Website.
NCT04268329
Hop Botanical Dietary Supplements - Metabolism and Safety in Women
NCT02848430
Primary Care-based Program to Enhance Positive Parenting Practices
NCT02871973
Proteomics and Stem Cell Therapy as a New Vascularization Strategy
NCT02802852
Online Collaborative Learning Intervention to Prevent Perinatal Depression
NCT02121015
Pharmacokinetics of Telavancin in Normal and Obese Subjects
NCT02753855
Engaging Newly Diagnosed Men About Cancer Treatment Options
NCT02668276
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
NCT02702518
Rejuvenation of Premature Ovarian Failure With Stem Cells
NCT02696889
Impact of No-carrageenan Diet on Glucose Tolerance in Prediabetes
NCT02720393
Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements
NCT02697877
Patient-Centered Anticoagulation Self-Monitoring in Minority Patients
NCT02776566
Interactions Between Drug Effects and Environments II
NCT03075501
Trial of Toothpaste to Reduce Plaque and Inflammation
NCT02666508
HET Bipolar System: Validation of Outpatient Hemorrhoid Treatment
NCT02773420
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02451748
Obesity, Iron Regulation and Colorectal Cancer Risk
NCT03548948
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
NCT02440568
Clinical Comparison of Vital Pulp Capping Restorative Protocols
NCT02635867
Investigational Oocyte Cryopreservation for Medical and Non Medical Indications
NCT04616417
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
NCT02444143
Asthma Action at Erie Trial
NCT02481986
Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
NCT02098369
Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
NCT02669706
Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes
NCT02319967
Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)
NCT01718444
Alternative Therapies for Improving Motor Impairment, Fall-risk and Overall Physical Function
NCT03758846
Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
NCT02409901
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
NCT02057523
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
NCT02132403
PATient Navigator to rEduce Readmissions
NCT02114515
DNase Treatment for Dry Eyes
NCT02193490
Effect of Adaptive Training for Balance Recovery
NCT02126488
A Behavioral Therapy for Insomnia Co-existing With COPD
NCT01973647
Racial and Aging Effects of Acute Antioxidant Supplementation
NCT02157207
Family Nutrition Physical Activity Tool Use During Well Child Visits
NCT02067728
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
NCT02043847
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
NCT02043860
Cortical Priming to Optimize Gait Rehabilitation Post Stroke
NCT03492229
Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment
NCT01903447
Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease
NCT02270515
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
NCT01639911
Seek, Test, Treat, Retain: An Integrated Jail-Prison-Community Model for Illinois
NCT01852877
Rehydration Following Exercise-Induced Dehydration
NCT01974986
COPD Assessment and Management Bundle Versus Usual Care
NCT01833026
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 43 |
| Phase 3 | 11 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the University of Illinois at Chicago pipeline
115 recruiting of 430 indexed (27% open); 236 completed (55%).
Phase mix: 30 late (III/IV) vs 80 early (I/II) (early-phase heavy).
Top condition: Multiple Sclerosis (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Illinois at Chicago: open-pipeline peers nationwide
Peers matched on 430 registered trials and 27% open enrollment, not the therapeutic-area sidebar.
University of Illinois at Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 430 trials (± recruiting share)
- Vanderbilt University · 430 trials · 3% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
- Dartmouth-Hitchcock Medical Center · 427 trials · 12% recruiting
Sponsors near 27% open enrollment (± trial volume)
- Coherus Oncology · 27% recruiting · 15 trials
- NewAmsterdam Pharma · 27% recruiting · 15 trials
- Portland VA Medical Center · 27% recruiting · 15 trials
- White River Junction Veterans Affairs Medical Center · 27% recruiting · 15 trials
Related
What to do with this University of Illinois at Chicago page
430 registered trials is a research-attention snapshot, not an endorsement of University of Illinois at Chicago or any single study.
- 115 of University of Illinois at Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition University of Illinois at Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Illinois at Chicago pipeline card: 430 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.